Gemcitabine in Combination With Either Cisplatin or Carboplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
Conditions
Lung Cancer
Conditions: official terms
Carcinoma, Non-Small-Cell Lung - Lung Neoplasms
Conditions: Keywords
stage IIIB non-small cell lung cancer, stage IV non-small cell lung cancer
Study Type
Interventional
Study Phase
Phase 3
Study Design
Allocation: Randomized, Primary Purpose: Treatment
Intervention
Name: carboplatin Type: Drug
Name: cisplatin Type: Drug
Name: gemcitabine hydrochloride Type: Drug
Overall Status
Recruiting
Summary
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, cisplatin, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. It is not yet known whether giving gemcitabine together with cisplatin is more effective than giving gemcitabine together with carboplatin in treating non-small cell lung cancer.

PURPOSE: This randomized phase III trial is studying gemcitabine and cisplatin to see how well they work compared to gemcitabine and carboplatin in treating patients with stage III or stage IV non-small cell lung cancer.
Detailed Description
OBJECTIVES:

Primary

- Compare the efficacy of gemcitabine in combination with 2 different doses of cisplatin vs carboplatin, in terms of survival time, in patients with stage IIIB or IV non-small cell lung cancer.

Secondary

- Compare symptom control and quality of life of patients treated with these regimens.

- Compare response in patients treated with these regimens.

- Compare the dose intensity of these regimens in these patients.

- Compare the ratio of courses of treatment given as in-patient vs out-patient in these patients.

- Compare the intensity and number and duration of toxic episodes in patients treated with these regimens.

- Compare cost and cost-effectiveness of these regimens in these patients.

OUTLINE: This is a randomized, multicenter study. Patients are stratified according to WHO performance status (0 vs 1 or 2), disease stage (IIIB vs IV), and participating center. Patients are randomized to 1 of 3 treatment arms.

- Arm I: Patients receive gemcitabine IV over 30 minutes on days 1 and 8 and cisplatin IV over 1 hour on day 1.

- Arm II: Patients receive gemcitabine as in arm I and cisplatin (at a lower dose than in arm I) IV over 1 hour on day 1.

- Arm III: Patients receive gemcitabine as in arm I and carboplatin IV over 1 hour on day 1.

In all arms, treatment repeats every 21 days for 2 courses. Patients are reassessed after 2 courses. Patients with responding disease or stable disease with symptom improvement receive 2 additional courses of therapy in the absence of disease progression or unacceptable toxicity. Patients with disease progression or stable disease without symptom improvement are removed from the study.

Quality of life is assessed at baseline, on day 1 of courses 2-4, at completion of study treatment, and then monthly for 6 months.

After completion of study treatment, patients are followed monthly for 6 months and then periodically thereafter for survival.

Peer Reviewed and Funded or Endorsed by Cancer Research UK

PROJECTED ACCRUAL: A total of 1,350 patients (450 per treatment arm) will be accrued for this study within 6 years.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: 18 Years
Gender: Both
Criteria: DISEASE CHARACTERISTICS:

- Histologically or cytologically confirmed non-small cell lung cancer (NSCLC), meeting 1 of the following stage criteria:

- Stage IIIB disease* that is not suitable for radical radiotherapy

- Stage IV disease* NOTE: *Radiographically verified

- At least 1 measurable lesion by clinical examination or radiography

- No mixed histologies of small cell lung cancer and NSCLC

- No clinically apparent brain metastases

PATIENT CHARACTERISTICS:

Age

- 18 and over

Performance status

- WHO 0-2

Life expectancy

- At least 12 weeks

Hematopoietic

- WBC ≥ 3,000/mm³

- Absolute neutrophil count ≥ 1,500/mm³

- Platelet count ≥ 100,000/mm³

- Hemoglobin ≥ 10 g/dL

Hepatic

- AST < 3 times upper limit of normal (ULN) (5 times ULN if liver metastases are present)

- Alkaline phosphatase < 3 times ULN

- Bilirubin < 1.5 times ULN

Renal

- Creatinine clearance ≥ 60 mL/min (by Wright equation) OR ≥ 70 mL/min (by ^51Cr-EDTA clearance)

Other

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- Able and willing to participate in the quality of life assessment

- No pre-existing neuropathy > grade 2

- No other malignancy that would preclude study treatment or study comparisons

- No evidence of severe or uncontrolled systemic disease, significant clinical disorder, or laboratory finding that would preclude study participation

- No psychiatric disorder that would preclude study participation

- No other condition that would preclude study compliance

PRIOR CONCURRENT THERAPY:

Biologic therapy

- No concurrent immunotherapy

Chemotherapy

- No prior chemotherapy, including neoadjuvant or adjuvant chemotherapy

- No other concurrent cytotoxic chemotherapy

Endocrine therapy

- No concurrent hormonal therapy except contraceptives or replacement steroids

Radiotherapy

- No prior radiotherapy

Surgery

- Recovered from prior surgery

- Prior surgical resection for NSCLC allowed

Other

- More than 12 weeks since prior investigational agents and recovered

- No other concurrent specific antitumor therapy

- No other concurrent investigational agents
Locations
Birmingham Heartlands Hospital
Birmingham, England, United Kingdom
Status: Recruiting
Contact: Joyce Thompson - 44-121-766-6611
Institute of Clinical Research - Birmingham
Birmingham, England, United Kingdom
Status: Recruiting
Contact: Hugh Jarrett - 44-121-414-6425
Start Date
March 2005
Sponsors
University Hospital Birmingham
Source
National Cancer Institute (NCI)
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page